Monopar Therapeutics (NASDAQ:MNPR) Price Target Raised to $133.00

Posted by Stanley Muller on Aug 15th, 2026

Monopar Therapeutics (NASDAQ:MNPR – Free Report) had its target price boosted by BTIG Research from $117.00 to $133.00 in a report published on Wednesday morning, MarketBeat reports. The brokerage currently has a buy rating on the stock.

Other equities analysts have also issued research reports about the company. Zacks Research upgraded Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 13th. HC Wainwright upped their price target on shares of Monopar Therapeutics from $105.00 to $125.00 and gave the company a “buy” rating in a research note on Wednesday, July 22nd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Monopar Therapeutics in a research note on Wednesday, July 15th. Piper Sandler set a $105.00 target price on shares of Monopar Therapeutics in a research report on Tuesday, June 2nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $117.42.

View Our Latest Stock Analysis on MNPR

Monopar Therapeutics Stock Performance

Shares of MNPR stock opened at $113.04 on Wednesday. Monopar Therapeutics has a 52-week low of $29.18 and a 52-week high of $124.82. The stock has a market cap of $758.50 million, a price-to-earnings ratio of -52.09 and a beta of 1.47. The firm’s 50-day moving average is $96.11 and its 200-day moving average is $71.53.

Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.02. Sell-side analysts predict that Monopar Therapeutics will post -2.95 EPS for the current fiscal year.

Institutional Trading of Monopar Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Wellington Management Group LLP bought a new stake in shares of Monopar Therapeutics during the third quarter worth about $18,904,000. Siren L.L.C. bought a new stake in Monopar Therapeutics during the 4th quarter worth approximately $13,863,000. Deerfield Management Company L.P. acquired a new position in Monopar Therapeutics in the 3rd quarter valued at approximately $13,048,000. RA Capital Management L.P. raised its stake in shares of Monopar Therapeutics by 30.5% during the fourth quarter. RA Capital Management L.P. now owns 667,207 shares of the company’s stock valued at $43,569,000 after acquiring an additional 156,000 shares during the last quarter. Finally, TCG Crossover Management LLC acquired a new position in shares of Monopar Therapeutics during the third quarter worth $12,496,000. Institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

(Get Free Report)

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.